ArticleEuropean journal of nuclear medicine and molecular imaging2017
[
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Association ofMolecular imaging and radionuclide therapy · 2026Article
- Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer.Advanced healthcare materials · 2026Article
- Hybrid [Bioengineering (Basel, Switzerland) · 2026Article
- Prognostic Significance of Pretreatment ¹⁸F-FDG PET/CT Parameters in Patients With ER+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Plus Endocrine Therapy.Korean journal of radiology · 2026Article
- Novel 4D radiomics applied to dynamic FES PET images to improve prediction of breast cancer response to ER-targeted therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Comparison between [EJNMMI research · 2026Article
- PET/CT Radiomics Integrated with Clinical Indexes as a Tool to Predict Ki67 in Breast Cancer: a Pilot Study.Nuclear medicine and molecular imaging · 2025Article
- New progress in imaging diagnosis and immunotherapy of breast cancer.Frontiers in immunology · 2025Review
- Overall survival and short-term efficacy analysis of cervical squamous cell carcinoma with skeletal muscle andScientific reports · 2024Article
- Assessment of androgen receptor expression in breast cancer patients using 18 F-FDG PET/CT radiomics and clinicopathological characteristics.BMC medical imaging · 2023Article
- How Radiomics Can Improve Breast Cancer Diagnosis and Treatment.Journal of clinical medicine · 2023Review
- Article
- Radiogenomics, Breast Cancer Diagnosis and Characterization: Current Status and Future Directions.Methods and protocols · 2022Review
- The value of whole-lesion histogram analysis based on field‑of‑view optimized and constrained undistorted single shot (FOCUS) DWI for predicting axillary lymph node status in early-stage breast cancer.BMC medical imaging · 2022Article
- eIF6 is potential diagnostic and prognostic biomarker that associated withJournal of translational medicine · 2022Article
- Synergistic impact of motion and acquisition/reconstruction parameters onMedical physics · 2022Article
- Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.Diagnostics (Basel, Switzerland) · 2022Review
- Can Radiomics Analyses inMolecular imaging and radionuclide therapy · 2022Article
- Habitat radiomics analysis of pet/ct imaging in high-grade serous ovarian cancer: Application to Ki-67 status and progression-free survival.Frontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the role of imaging features derived from [
methodsImages from 43 patients with a first diagnosis of BC were reviewed. Images were acquired before any treatment. Histological data were derived from pretreatment biopsy or surgical histological specimen; these included tumor type, grade, ER and PgR receptor status, lymphovascular invasion, Ki67 index, HER2 status, and molecular subtype. Standard parameters (SUV
resultsA significant correlation was found between some advanced imaging features and the histological type. Different molecular subtypes were characterized by different values of two histogram-based features (median and energy). A significant association was observed between the imaging signature and luminal A and luminal B HER2 negative molecular subtype and also when considering luminal A, luminal B HER2-negative and HER2-positive groups. Similar results were found between the signature and all five molecular subtypes and also when considering the histological types of BC.
conclusionsOur results suggest a complementary role of standard PET imaging parameters and advanced imaging features for the in vivo biological characterization of BC lesions.
Indexed as
Identifiers
28711994What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.